Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine M Bever

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic CancerAnnie A Wu, Katherine M Bever, Won Jin Ho, et al.
Cancer Immunology Research|January 12, 2026
A randomized phase II study: CRS207/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDACKatherine M Bever, Amanda L Huff, Ludmila Danilova, et al.
Cancer Immunology Research|January 12, 2026
Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor ResponsesDimitri N Sidiropoulos, Zhehao Zhang, Jennifer N Durham, et al.
Oncotarget|June 12, 2020
An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinomaKatherine M Bever, Erkut H Borazanci, Elizabeth A Thompson, et al.
Oncoimmunology|August 15, 2025
A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophagesKatherine M Bever, Sarah M Shin, Jennifer N Durham, et al.
JCI Insight|August 6, 2024
Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinomaNicole E Gross, Zhehao Zhang, Jacob T Mitchell, et al.
Nature Communications|June 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trialHejia Henry Wang, Amanda L Huff, S Daniel Haldar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancerEric S Christenson, Won Jin Ho, Daniel Shu, et al.
Cancer Discovery|July 16, 2026
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohortsS Daniel Haldar, Amanda L Huff, Hejia Henry Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2020
Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic AdenocarcinomaLei Zheng, Ding Ding, Barish H Edil, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic CancerAnnie A Wu, Katherine M Bever, Won Jin Ho, et al.
Cancer Immunology Research|January 12, 2026
A randomized phase II study: CRS207/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDACKatherine M Bever, Amanda L Huff, Ludmila Danilova, et al.
Cancer Immunology Research|January 12, 2026
Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor ResponsesDimitri N Sidiropoulos, Zhehao Zhang, Jennifer N Durham, et al.
Oncotarget|June 12, 2020
An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinomaKatherine M Bever, Erkut H Borazanci, Elizabeth A Thompson, et al.
Oncoimmunology|August 15, 2025
A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophagesKatherine M Bever, Sarah M Shin, Jennifer N Durham, et al.
JCI Insight|August 6, 2024
Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinomaNicole E Gross, Zhehao Zhang, Jacob T Mitchell, et al.
Nature Communications|June 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trialHejia Henry Wang, Amanda L Huff, S Daniel Haldar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancerEric S Christenson, Won Jin Ho, Daniel Shu, et al.
Cancer Discovery|July 16, 2026
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohortsS Daniel Haldar, Amanda L Huff, Hejia Henry Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2020
Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic AdenocarcinomaLei Zheng, Ding Ding, Barish H Edil, et al.
Pageof 3